PHAT stock forecast
Our latest prediction for Phathom Pharmaceuticals Inc's stock price was made on the June 10, 2021 when the stock price was at 34.92$.
In the short term (2weeks), PHAT's stock price should underperform the market by -3.36%. During that period the price should oscillate between -12.48% and +9.87%.
In the medium term (3months), PHAT's stock price should underperform the market by -4.70%. During that period the price should oscillate between -39.61% and +25.23%.Get email alerts
Create a solid portfolio with PHAT
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.22$ per share.
The book value per share is 7.87$
Three months stock forecastJune 10, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|